Torrent Pharma's Q1 Revenue Jumps 55% on Acquisition, But Profit Growth Lags
The pharmaceutical major's revenue surged past ₹4,900 crore, though net profit margin fell sharply year-on-year, highlighting integration costs.
Torrent Pharmaceuticals reported a 54.8% YoY revenue surge in Q1 FY27, driven by its JB Chemicals acquisition. Profit growth was a modest 3.3%, with net profit margin contracting significantly.
Torrent Pharmaceuticals delivered a quarter of powerful revenue growth but weaker profitability, as its landmark acquisition of JB Chemicals & Pharmaceuticals began to reshape the business. Revenue for Q1 FY27 soared 54.8% year-on-year to ₹4,921 crore, while profit after tax grew a more modest 3.3% to ₹566 crore. This divergence highlights the initial costs of integrating a major acquisition, even as it significantly boosts the company's domestic market scale.
The story is clearer when looking at the recent quarterly trajectory. While revenue has climbed steadily over the past year, profit and net profit margin have been more volatile. The net profit margin for the latest quarter stood at 11.5%, a sharp contraction from 17.2% in the same quarter last year.
Revenue (₹ Cr.)
Profit (₹ Cr.)
Net Profit Margin (%)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Revenue (₹ Cr.) | 4,921YoY +55% | 4,197 | 3,178 |
| Profit (₹ Cr.) | 566YoY +3.3% | 364 | 548 |
| Net Profit Margin (%) | 11.5YoY -33% | 8.7 | 17.2 |
The sequential view shows a strong rebound from a weak Q4, with profit jumping 55.5% quarter-on-quarter and margins recovering from 8.7% to 11.5%. Over the trailing twelve months, the company maintained a healthier net profit margin of 13.7% on revenue of ₹15,723 crore.
Key Points
- The company's return on equity remains robust at 26.8%, indicating efficient use of shareholder capital.
- The stock has delivered strong returns, gaining 33.4% over the past year and 145.1% over three years.
- At a P/E of 66, the stock trades at a significant premium to the industry average of 38, reflecting high growth expectations post-acquisition.
The immediate challenge for Torrent Pharma is to translate its enlarged revenue base into sustained profit margin improvement as integration synergies materialize.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.